Boston Scientific, Medtronic and GlaxoSmithKline returned to support a $30m series D round for biomedical technology company SetPoint Medical.
US-based biomedical technology developer SetPoint Medical obtained $30m in a series D round yesterday that included medical device manufacturers Boston Scientific and Medtronic as well as pharmaceutical firm GlaxoSmithKline (GSK).
The round also featured New Enterprise Associates (NEA), Morgenthaler, Topspin and other unnamed backers. GSK participated through its Action Potential Venture Capital (APVC) subsidiary.
SetPoint is developing a bioelectronic medicine platform that uses a small implanted device to treat chronic, debilitating inflammatory diseases by stimulating the vagus nerve, activating the…